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Abstract Ketamine, an N-methyl-D-aspartate receptor
(NMDAR) antagonist, has been studied in relation to the glu-
tamate hypothesis of schizophrenia and increases dissociation,
positive and negative symptom ratings. Ketamine effects brain
function through changes in brain activity; these activity pat-
terns can be modulated by pre-treatment of compounds
known to attenuate the effects of ketamine on glutamate re-
lease. Ketamine also has marked effects on brain connectivity;
we predicted that these changes would also be modulated by
compounds known to attenuate glutamate release. Here, we
perform task-free pharmacological magnetic resonance imag-
ing (phMRI) to investigate the functional connectivity effects of
ketamine in the brain and the potential modulation of these
effects by pre-treatment of the compounds lamotrigine and ris-
peridone, compounds hypothesised to differentially modulate
glutamate release. Connectivity patterns were assessed by com-
biningwindowing, graph theory andmultivariate Gaussian pro-
cess classification. We demonstrate that ketamine has a robust
effect on the functional connectivity of the human brain com-
pared to saline (87.5 % accuracy). Ketamine produced a shift
from a cortically centred, to a subcortically centred pattern of
connections. This effect is strongly modulated by pre-treatment
with risperidone (81.25 %) but not lamotrigine (43.75 %).
Based on the differential effect of these compounds on keta-
mine response, we suggest the observed connectivity effects are
primarily due to NMDAR blockade rather than downstream
glutamatergic effects. The connectivity changes contrast with
amplitude of response for which no differential effect between
pre-treatments was detected, highlighting the necessity of these
techniques in forming an informed view of the mechanistic
effects of pharmacological compounds in the human brain.
Keywords Glutamate . NMDA receptor . fMRI . Drug
discrimination . Imaging . Schizophrenia . Thalamus .
Connection
Introduction
The N-methyl-D-aspartate receptor (NMDAR) antagonist ke-
tamine induces glutamatergic dysfunction in healthy humans
which can lead to the acute onset of psychomimetic symptoms
resembling schizophrenia (Krystal et al. 1994; Goff and
Coyle 2001; Corlett et al. 2011). Whilst not a pheno-
copy of the disorder, ketamine causes an increase in
both positive and negative symptom scores as well as
impairing cognition (Dsouza et al. 1994; Honey et al.
2008). Hence, it has been widely used to study the role
of glutamatergic dysfunction in relation to schizophrenia
(Lahti et al. 1995).
Ketamine has been shown to elicit robust and reliable
effects on the blood oxygen level-dependent (BOLD)
signal in healthy volunteers (Deakin et al. 2008; De
Simoni et al. 2013; Driesen et al. 2013). To date, these
BOLD effects have been primarily studied in terms of
their amplitude (Deakin et al. 2008; De Simoni et al.
2013; Doyle et al. 2013a). Moreover, pre-treatment with
compounds expected to reduce glutamate release has
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been demonstrated to attenuate the ketamine-induced
BOLD response (Deakin et al. 2008; Doyle et al.
2013a).
Previously, we demonstrated that acute pre-treatment
with clinically effective doses of either lamotrigine or
risperidone attenuated the BOLD response to ketamine
infusion in healthy volunteers via different mechanisms
of action (Doyle et al. 2013a). Lamotrigine, an anticon-
vulsant, acts pre-synaptically through sodium ion chan-
nel modulation, attenuating glutamate release directly
(Large et al. 2005). In contrast, risperidone, an atypical
antipsychotic, is thought to alter cortical glutamate
levels pre-synaptically through 5-HT2A receptor antago-
nism, indirectly reducing glutamate release (Meltzer et
al. 2011). Moreover, risperidone has been shown to po-
tentiate NMDARs directly (Konradsson et al. 2006) pro-
viding an additional potential mechanism of action to
attenuate the ketamine-evoked effect.
Acute NMDAR blockade has been shown to alter the func-
tional connectivity of several neural systems in both rodents
(Gass et al. 2013) and humans (Niesters et al. 2012; Driesen et
al. 2013). The mechanism by which this is achieved is not
understood. It is presumed that the downstream effects on
the glutamate system drive connectivity changes, but evidence
for this is lacking.
Here, we address the question of how an acute ketamine
infusion affects the pattern of whole-brain connectivity and
how this is altered through different modulatory mechanisms
using risperidone and lamotrigine as pharmacological probes.
If purely a result of direct NMDA blockade, we hypothesise
that any changes in connectivity will be insensitive to the
effects of lamotrigine whilst attenuated by risperidone. We
would interpret shared effects by both lamotrigine and risper-
idone as resulting from the presumed attenuation of glutamate
release.
Pattern recognition (PR) techniques have been used
to perform single subject inference using whole brain
functional connectivity data to model disease states
(Craddock et al. 2009; Zhang et al. 2011; Richiardi et
al. 2012), cognitive states (Richiardi et al. 2011; Shirer
et al. 2012) and age groups (Dosenbach et al. 2010). In
the current study, we use whole-brain measures of func-
tional connectivity with PR techniques to identify spa-
tial patterns of whole-brain connectivity underlying the
effects of acute ketamine and to investigate the extent
of the effect of pre-treatment on this induced connectiv-
ity pattern. In accord with our BOLD signal amplitude
response findings (Doyle et al. 2013a), we expect both
compounds to exhibit modulation of the ketamine-in-
duced change. We predict that the extent and pattern
of each compound’s modulatory effect will provide in-
sight into the neuronal systems underlying the ketamine
effect in the human brain.
Materials and methods
Participants
Twenty right handed male volunteers were recruited for
this double blind, placebo controlled, cross-over design
study, approved by the Wandsworth Research Ethics
Committee (09/H0803/48). Participants provided written
informed consent and were screened for any history of
physical, neurological and psychiatric illness. Further
exclusion criteria included MRI-incompatibilities, illicit
drug abuse and excessive alcohol, cigarette or caffeine
consumption, in addition to normal ranges on standard
haematology and biochemistry assessments. Further de-
tails are available in Doyle et al. (2013a). Twenty par-
ticipants passed screening and were entered into the
study, of which four withdrew, one due to fainting upon
cannulation in session 1, one experiencing nausea at
session 3 and two participants were withdrawn at ses-
sion 2 and session 3 due to violating the lifestyle guide-
lines. Thus, 16 participants (range=20–37; mean=25.8;
SD=5.7) completed all sessions in this study.
Experimental design
Data were collected over four sessions, each separated
by a period of at least 10 days. During each session,
participants received a single oral dose of either
lamotrigine (300 mg), risperidone (2 mg) or placebo
(ascorbic acid; two sessions). This was followed by an
intravenous infusion of either saline or ketamine, to a
target plasma level of 75 ngml−1, timed to coincide with
the approximate expected time of maximum plasma
concentration of both compounds. The administered
pre-treatment and infusion combinations were placebo
and saline, placebo and ketamine, risperidone and keta-
mine and lamotrigine and ketamine. The compound
combinations and session timelines are illustrated in
Fig. 1. Imaging procedures for risperidone and
lamotrigine sessions were undertaken during the broad
maximum plasma exposure between 1 h 30 m post-dose
(oral drug alone) and 4 h 15 m post-dose during keta-
mine infusion. At 30 min, 1, 1.5, 4 and 8 h following
the administration of the oral compounds, blood samples
were taken to measure risperidone and lamotrigine con-
centrations in plasma.
Compound infusion
A sub-anaesthetic dose of racemic ketamine was admin-
istered intravenously to achieve a target plasma level of
75 ngml−1, adjusted for the participant’s weight and
height measured at each sess ion . In t ravenous
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administration was achieved using a Graseby 3400
pump based on the Clements 250 model and was con-
trolled using Stanpump (http://anesthesia.standford.edu/
pkpd). A dose of 0.12 (±0.003 SD)mgkg−1 was
administered in the first minute followed by a pseudo-
continuous infusion of approximately 0.31 mgkg−1 h−1.
Blood samples were taken at 15 and 75 min after the
start of the infusion to measure ketamine concentration
in the plasma.
MRI acquisition
MR images were acquired using a 3T GE HDx scanner. Gra-
dient-echo echo-planar imaging (EPI) was used to acquire 450
task-free volumes of 38 near-axial slices over a period of
15 min for each session (3 mm thickness, 0.3 mm inter-slice
gap, TE=30ms, TR=2000ms, FA=75°, in-plane resolution=
3.3 mm, matrix size=64×64, field of view=21.1×21.1 cm).
The infusion of ketamine or saline was administered 5 min
into the 15 min scan. Additionally, a high-resolution gradient-
echo scan was performed resulting in 43 near-axial slices
(3 mm thickness, 0.3 mm inter-slice gap, TE=30 ms, TR=
2000 ms, FA=90°, in-plane resolution=3.3 mm, matrix size=
128×128, field of view=24×24 cm).
Experimental conditions
The 450 volumes of the EPI time series acquired at each ses-
sion were divided into pre- and post-infusion conditions, de-
fined as the first and last 150 volumes (5 min) of data, respec-
tively. The pre-infusion condition corresponds to the period
during which participants had only the oral compound present
and the post-infusion condition corresponds to the period 5–
10 min after the administration of bolus. We refer to pre- and
post-infusion conditions in each compound combination ses-
sion using the naming scheme described in Table 1.
Pre-processing
Imaging data were pre-processed using SPM5 (www.fil.ion.
ucl.ac.uk/spm). The BOLD time series were slice-time
corrected, realigned to the first volume then to the mean
volume, co-registered to the high-resolution structural scan,
spatially normalised to the SPM EPI template and smoothed
Fig. 1 Timeline for each experimental sessions by time of day. Four
compound combinations were administered in four separate sessions
separated by a period of at least 10 days. Participants received an oral
pre-treatment before receiving an intravenous infusion of ketamine or
saline with the administered compound combinations of placebo-saline,
placebo ketamine, risperidone-ketamine and lamotrigine-ketamine. 156×
99mm (300×300 DPI)
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using a Gaussian kernel of 8 mm at full-width half-maximum.
The structural images were segmented into grey matter, white
matter and cerebrospinal fluid (CSF) tissue types.
Linear regression was used to regress out nuisance signal
parameters from the imaging time-series data, specifically the
mean CSF signal, mean WM signal and the six motion pa-
rameters. The mean and maximum head motion parameters
were compared between compound infusion conditions with-
in each session. No differences in motion were observed at p<
0.05 (uncorrected). A band pass filter of 0.01–0.1 Hz was
subsequently applied to reduce the effect of high-frequency
(>0.1 Hz) physiological signals and low-frequency (<0.01Hz)
noise such as scanner drift.
Connectivity graph generation
Parcellation
The pre-processed data were parcellated into regions to
facilitate network analysis where each parcellated region
represents a node in a graph. The automated anatomical
labelling (AAL) atlas (Tzourio-Mazoyer et al. 2002) was
selected to parcellate the brain into 116 anatomical nodes
due to its prevalence in neuroimaging studies (Zalesky et
al. 2010; Braun et al. 2012). A finer scale parcellation
would provide increased regional homogeneity but compli-
cates the interpretation of the model (Faria et al. 2012).
Node time series were calculated as the mean of voxel time
courses in each atlas region. In this manner, the entire brain
can be represented as a graph, G=(V, E), where V describes
the collection of 116 nodes (defined in the AAL Atlas) and
E the edges between each node pair.
Task-free spatiotemporal dynamics
Task-free or “resting state” networks (RSNs) display complex
spatiotemporal dynamics. Networks identified from resting
state data are highly dependent on the temporal scale used
(Hutchison et al. 2012). In order to account for these dynam-
ics, temporal windowing may be applied (Allen et al. 2012).
RSNs derived from long windows (>~120 s) allow investiga-
tions of the core network and minimise the effects of spurious
correlations which occur with brief acquisitions. Furthermore,
it has been demonstrated that RSNs can be considered stable
when windowing at >~240 s (Van Dijk et al. 2010; Hutchison
et al. 2012). To this end, a moving window of length T=120
volumes (240 s) windowwas applied over the parcellated time
series data for each condition in order to compute temporal
connectivity.
A tapered window was preferred to a box car in order to
minimise overlap between windows and reduce the contribu-
tion of any outliers not central to the window. We define the
window using the Gaussian window function:
W tð Þ ¼ exp − t
2
2s2
 
where t takes values {−T/2 .. T/2} and s is defined as T/6. This
window was applied in increments of 2s, the effective length
of the window, resulting in eight windowed time-series for
each condition.
In the present study, although no specific task was applied
during the functional scan, the paradigm likely induces some
departure from the “resting state” due to the expectation of
drug delivery pre-infusion and putative subjective effects of
ketamine following its infusion.
Network formulation
The edges, E, were calculated between all pairs of nodes in V
using linear correlation resulting in a series of adjacency ma-
trices for each window position, as illustrated in Fig. 2. In this
manner, we express the functional connections between re-
gions across the whole brain whilst accounting for low-fre-
quency network dynamics thought to represent “core” con-
nections (Hutchison et al. 2012).
Centrality measure
Using graph theory centrality measures, it is possible to quan-
tify the importance or “connectedness” of node within a graph
(Rubinov and Sporns 2010). The most intuitive of these mea-
sures is weighted degree centrality which is simply the sum of
the weights of all edges impingent on a given node and has
been previously demonstrated to be well-suited to elucidate
node properties within brain networks (Buckner et al. 2009;
Lord et al. 2012). As a local measure, it provides an indication
of the connectedness of a brain region with the rest of the
brain. Degree centrality was selected for this investigation as
it provides an intuitive measure of the overall connectedness
of a region. Given the wide spread effects of glutamatergic
Table 1 Naming convention for each individual drug state in each of
the four compound combinations
Name Description
Placebo (pre-Sal) Placebo, prior to saline infusion
Placebo (pre-Ket) Placebo, prior to ketamine infusion
Risperidone Risperidone pre-treatment prior to ketamine infusion
Lamotrigine Lamotrigine pre-treatment prior to ketamine infusion
Saline Saline infusion given after placebo (pre-Sal)
Ketamine Ketamine infusion given after placebo (pre-Ket)
Lam+ketamine Ketamine infused given after lamotrigine
Ris+ketamine Ketamine infused given after risperidone
Ket ketamine, Lam lamotrigine, Ris risperidone, Sal saline
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dysfunction, providing a measure of how the mean connectiv-
ity of a region with the rest of the brain is affected. Here, the
degree centrality (DC) was calculated for each node, i, in each
adjacency matrix using:
DC ið Þ ¼ ∑
N
j¼1
ai j
where N is the number of nodes (N=116) and aij is the edge
weighting between nodes i and j in the adjacency matrix A.
Measures at each network slice were normalised by network
density to account for inter-subject differences in network
densities.
Pattern recognition
To perform comparisons between session conditions, Gauss-
ian process classification (GPC) was employed. This binary
classification algorithm provides probabilistic predictions of
class membership for unseen test data based on a model de-
fined from a set of training data and their respective labels
(either +1 or −1). It has been demonstrated to provide robust
performance in several neuroimaging studies (Marquand et al.
2010; 2011; Doyle et al. 2013a; Young et al. 2013). For a more
detailed account of this technique, please refer to (Rasmussen
and Christopher 2006). The subject-wise mean centred DC
measures from all window positions in each session condition
were used as a feature set for classification, allowing for the
comparison of regional network connectedness between
conditions.
In order to assess the performance of the classifier, leave-
one-out cross validation (LOOCV) was used. This is an iter-
ative process whereby data from all but one participant is used
for training; data from the withheld participant is then used for
testing. The reported classification accuracy is the mean accu-
racy value obtained across all LOOCV folds. This accuracy
serves to quantify the degree to which the two groups can be
separated in terms of their functional connectivity as measured
by DC.
The statistical significance of the classification accuracy
was assessed by permutation. A distribution of permuted ac-
curacies was generated by re-training the classifierNperm times
using randomly permuted class labels. The number of times
the permuted accuracy was found to be greater than the true
accuracy was counted and divided by Nperm to provide an
estimate of the p value (here, Nperm=1000). As several con-
trasts were investigated, Bonferroni correction was applied to
correct for the effect of multiple comparisons.
Classification was performed using the following two
configurations: (1) between PLA+SAL and PLA+KET
sessions in order to investigate the effect of ketamine on
whole-brain connectivity and (2) using lamotrigine and
risperidone pre-treated sessions (LAM+KET and RIS+
KET) in contrast to the PLA+KET and PLA+SAL ses-
sions to investigate their modulation of ketamine-induced
connectivity.
Fig. 2 Series of network adjacency matrices obtained using correlations
between all node pairs within each window position. Windowing was
performed using a moving tapered window of 120 volumes (4 min)
applied to each 150 volume (5 min) condition to examine dynamics in
the task-free data. 171×103mm (300×300 DPI)
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Ordinal regression using Gaussian processes (ORGP)
(Doyle et al. 2013b) was applied to investigate the relationship
between experimental conditions, identifying an ordinal trend
across classes under the proviso that classes are rank ordered.
Classes may be accurately distinguished from one another
only if an ordinal progression exists between classes, else poor
discrimination may be observed. We refer the reader to Chu
and Ghahramani (2005) for further details on this multi-class
classification algorithm.
Classification maps
Multivariate classification maps (g-maps) were generated for
models with significant classification accuracy (identified by
permutation tests), allowing for the visualisation of the dis-
criminating pattern of spatial covariance driving the classifi-
cation (Marquand et al. 2010).
Samples were weighted in relation to their class typicality,
resulting in a visualisation of the distribution of the classes
relative to one another. For each map, node weights were
depicted as spheres positioned in MNI space at the centre of
mass for the corresponding AAL regions. The size of these
spheres represents the contribution of the node in driving the
discriminatory performance. The colour, blue or red, repre-
sents the sign of the weights, recalling that the class labels
are encoded as either +1 or −1 (e.g. +1=PLA+KET and
−1=PLA+SAL). A high positive weight implies that the
weighted average DC for that node was higher for the class
with the positive label +1 (e.g. the PLA+KET class). We note
this weighted average is influenced by a combination of the
DC value, its variance and the classification parameterisation.
The direction of change in node strength between classifica-
tion groups was confirmed using paired t tests. One sample t
tests were performed on the node deltas between classes for
the purpose of qualitative analysis only. Significance was in-
dicated at p<0.05; we have not used formal multiple compar-
isons correction to balance type I and type II errors as the core
inferences of this paper were drawn from the multivariate
analysis and not this supplementary univariate analysis.
Results
Ketamine robustly alters the whole-brain functional
connectivity pattern
In order to determine the effect of ketamine on the pattern on
degree centrality (DC), the ketamine condition was compared
against both pre-infusion placebo (PLA+KET) and saline
conditions which involved no active pharmacology. These
comparisons yielded high classification accuracies reflecting
significant differences in functional connectivity (Acc=81.25
and 87.5 %, respectively, p<0.003 and p<0.001; Table 2).
Importantly, the classifier was unable to significantly dis-
tinguish between both the two pre-infusion conditions follow-
ing administration of oral placebo (placebo pre-ketamine v
placebo pre-saline) with a classification accuracy (68.75 %,
p>0.05) and conditions before and after a saline infusion (pla-
cebo (pre-saline) v saline, Acc=62.5 %, p>0.05) (Table 2).
These findings indicate that within the context of our study
design, we cannot discriminate between placebo (pre-saline)
and saline conditions; this is akin to within-session stability.
Furthermore, it was not possible to discriminate between pla-
cebo conditions which are akin to between-session stability.
Figure 3c illustrates the pattern of weights (g-map) driving
the classification between the placebo (pre-ketamine) and ke-
tamine conditions. Qualitatively, the pattern of node weights
favouring the ketamine condition (depicted in red) is strongly
represented in sub-cortical and cerebellar regions whereas the
pattern of weights favouring placebo (pre-ketamine, depicted
in blue) is predominantly cortical, especially in occipital, tem-
poral, medial temporal and frontal cortical regions. A regional
visualisation of the weight distributions is presented in Fig. 3a.
This pattern of features was highly similar to that of the g-map
of saline infusion compared to ketamine infusion, suggesting a
similar effect driving the classification in both comparisons.
Post hoc t tests performed directly on the DC values confirm
the regions exhibiting increased DC, in relation to placebo, fit
with the pattern of positive weights favouring ketamine, and
vice versa for the pattern of negative weights. A summary
figure illustrating the univariate change in DC values for each
node within each region is shown in Fig. 3b.
Pre-treatment with risperidone alters
the ketamine-induced functional connectivity pattern
To investigate the effect of modulating the ketamine response
by risperidone, classification was performed by comparing
each of the RIS+KET sessions against both the placebo ses-
sions (PLA+KET and PLA+SAL) as shown in Table 3.
The DC pattern for the risperidone pre-treated ketamine
condition was significantly discriminated from saline (saline
v ris+ketamine, Acc=81.25 %, p>0.05) suggesting a dissim-
ilar pattern of DC between conditions. Furthermore, the
Table 2 Results of PLA-SAL and PLA-KET classification using GPC
Contrast Accuracy (%) p value
Placebo (pre-Sal) v Placebo (pre-Ket) 68.75 0.52
Placebo (pre-Sal) v Saline 62.5 0.124
Placebo (pre-Ket) v Ketamine 81.25 0.003*
Saline v Ketamine 87.5 0.001*
Reported accuracies obtained with LOOCV and significance with (N=
1000) permutation testing
*Indicates results passing Bonferroni correction
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risperidone pre-treated ketamine condition was significantly
discriminated from the placebo pre-treated ketamine condition
(ketamine v ris+ketamine, Acc=81.25 %, p<0.001) indicat-
ing risperidone modulates the ketamine effect on DC; classi-
fication map is shown in Fig. 4c. This suggests a distinct
risperidone state, different from both ketamine and saline.
The spatial pattern of weights for ketamine pre-treated with
risperidone was to some degree similar to ketamine pre-treated
with placebo (Fig. 3c) with the notable exception of the
weighting of nodes in occipital regions; this can best be ob-
served in Fig. 4a. To investigate the univariate change in DC
values, t tests were performed on the delta of ris+ketamine
and ketamine conditions, Fig. 4b. Risperidone pre-treatment
was observed to modulate ketamine-induced connectivity
resulting in increased DC in the frontal and temporal cortices
and decreased DC in the basal ganglia, occipital and parietal
regions, when compared to placebo pre-treated ketamine.
Moreover, when comparing the pre- and post-ketamine in-
fusion conditions for the risperidone pre-treated session, the
Table 3 GPC classification using RIS+KET, LAM+KET, PLA+SAL
and PLA+KET conditions, showing the effect of lamotrigine and
risperidone pre-treatment on the ketamine-effected centrality
Contrast Accuracy (%) p value
Placebo (pre-saline) v Risperidone 75.00 0.007
Saline v Ris+ketamine 81.25 0.001*
Risperidone v Ris+ketamine 62.5 0.17
Ketamine v Ris+ketamine 81.25 0.001*
Placebo (pre-saline) v Lamotrigine 32.125 1
Saline v Lam+ketamine 93.75 0.001*
Lamotrigine v Lam+ketamine 87.5 0.001*
Ketamine v Lam+ketamine 43.75 0.872
Lamotrigine v Risperidone 62.5 0.154
Lam+ketamine v Ris+ketamine 93.75 0.001*
Reported accuracies obtained with LOOCV and significance with (N=
1000) permutation testing
*Indicates a results passing Bonferroni correction
Fig. 3 Results of univariate and multivariate analysis of node centrality
for ketamine and placebo. a Distribution of classification weights within
brain regions for the comparison of placebo (pre-ket; Blue) and ketamine
(Red). Bars represent percentage membership for each class within the
specified region. b Effect of ketamine on node DC values compared to
placebo. One sample t-statistics for node changes (plabebo (pre-ket)—
ketamine) summarised across brain regions. Positive values represent a
ketamine-induced increase in DC in comparison to placebo. Filled circles
signify significance, set at p<0.05. c Visualisation of main effects of
ketamine, g-map for classification between placebo (pre-ket; Blue) v ke-
tamine (Red). Nodes correspond spatially to AAL regions and are shown
with radii linearly scaled to indicate relative weighting. Red nodes exhib-
ited increased centrality in t-maps, blue nodes exhibited decreasing cen-
trality. 177×133mm (300×300 DPI)
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classifier was unable to significantly separate these conditions
(risperidone v ris+ketamine, Acc=62.5 %, p>0.05). The re-
sults of these three comparisons are all consistent with risper-
idone pre-treatment modulating the ketamine-induced func-
tional connectivity pattern as measured by DC.
Whilst the results of these comparisons are consistent with
risperidone modulating the ketamine-induced connectivity
pattern, it is also possible that the classifications are driven
by a common risperidone signature. That is, the main effect
of risperidone may be present during both the risperidone and
the ris+ketamine conditions. Thus, we propose that we are
observing an interaction effect between risperidone and the
ketamine response. This is in keeping with our hypothesis that
risperidone has a substantial effect on the pattern of ketamine
DC.
The risperidone pre-treated ketamine condition was classi-
fied using the GPC model trained using saline and ketamine
classes (Table 4). Risperidone pre-treated ketamine was
confused with both saline and ketamine conditions with
chance level accuracies reported. A marginally higher accura-
cy was reported for the confusion with the ketamine condition
than the saline.
Fig. 4 Results of univariate and multivariate analysis of centrality for
ketamine pre-treated with placebo and risperidone. a Distribution of clas-
sification weights within brain regions for the comparison of Ris+keta-
mine (Blue) and ketamine (Red). Bars represent percentage membership
for each class within the specified region. b Change in DC values due to
risperidone pre-treatment of ketamine-induced changes. One sample t-
statistics for node changes (defined as Ris+Ket—ketamine) summarised
across brain regions. Filled circles signify significance, set at p<0.05. c
Effects of risperidone pre-treatment on ketamine-induced centrality
changes, classification of Ris+ketamine (Blue) v ketamine (Red). Nodes
correspond spatially to AAL regions and are representative linearly scaled
to indicate relative weighting. Red nodes exhibit increasing centrality in t-
maps, blue nodes, decreasing centrality. 173×134mm (300×300 DPI)
Table 4 Confusion matrix for the classification of risperidone+
ketamine using the GPC model obtained from training on saline and
ketamine conditions
Testing was performed using leave-one-subject-out cross validation
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Pre-treatment with lamotrigine does not alter
the ketamine-induced functional connectivity pattern
To investigate the effect of lamotrigine pre-treatment on keta-
mine-induced changes in functional connectivity, we com-
pared both the lamotrigine conditions against the placebo
post-infusion sessions (PLA+KETand PLA+SAL) as shown
in Table 3.
It was not possible to discriminate lamotrigine from
placebo (lamotrigine v placebo (pre-sal), Acc =
32.125 %, p>0.05), suggesting similar patterns of DC
in both conditions. There was no supportive evidence of
a significant modulation effect of the ketamine-induced
DC pattern by lamotrigine (ketamine v lam+ketamine,
Acc=43.75 %, p>0.05). Furthermore, similar trends
were observed when comparing the pre-infusion and
post-infusion ketamine states for the placebo sessions
(placebo (pre-ket) v ketamine, Acc=81.5 %, p<0.001)
and lamotrigine pre-treatment (lamotrigine v Lam+keta-
mine, Acc=87.5 %, p=0.01). Taken together, our results
suggest lamotrigine pre-treatment, at the administered
dosage, does not have an effect on ketamine-induced
DC patterns.
We were unable to distinguish between both lamotrigine
and risperidone sessions when compared directly (lamotrigine
v risperidone, Acc=62.5 %, p>0.05). However, a significant
classification accuracy was observed for the comparison be-
tween post-ketamine conditions following a pre-treatment of
lamotrigine and risperidone (lam+ketamine v ris+ketamine,
Acc=93.75 %, p<0.001). This suggests both compounds dif-
ferentially affect the pattern of ketamine-induced DC.
Ketamine plasma concentrations in the experimental ses-
sions were correlated to participant posterior probabilities for
the within session classification (pre-infusion vs. post-infu-
sion). No significant correlation was observed at a level of p
<0.05. This suggests the observed patterns of DC do not lin-
early scale with the ketamine plasma concentrations.
Ordinal regression
Ordinal regression was performed to investigate any potential
attenuative effects of lamotrigine and risperidone on the keta-
mine-induced change in connectivity. Specifically, two analy-
ses were performed with conditions rank ordered: (1) saline v
(Ris+ketamine) v ketamine and (2) saline v (Lam+ketamine)
v ketamine. As shown in Table 5, no ordinal trend was ob-
served between saline and ketamine for (ris+ketamine) and
(lam+ketamine) conditions. For configuration 1, saline
is distinctly and accurately identified; however, the ke-
tamine and the lam+ketamine classes exhibit confusion
with each other. In configuration 2, saline and ketamine
are well distinguished from each other; however, the
ris+ketamine condition reports confusion with both con-
ditions and is not well identified.
Discussion
Using whole brain centrality metrics in a multivariate frame-
work, we were able to show that ketamine induces a robust,
predictable change in the functional connectivity pattern in the
human brain, producing a shift from a cortically centred to a
sub-cortically centred brain state. Risperidone pre-treatment
significantly modulated the ketamine-induced centrality
changes; however, lamotrigine did not. The distinct modula-
tory effects of these two compounds on ketamine-induced DC
changes stands in contrast to their similar effects in attenuating
the ketamine-induced BOLD amplitude changes.
Ketamine infusion
Consistent with previous work, during a task-free acute keta-
mine challenge, a distributed pattern of functional connectiv-
ity changes were observed across the brain. On contrasting
ketamine with placebo, nodes in the basal ganglia and
Table 5 Confusion matrices for ORGP classification of (A) saline v
lam+ketamine v ketamine and (B) saline v ris+ketamine v ketamine, no
significant discrimination was observed for the pre-treated classes in
relation to saline and ketamine, as indicated by the less than chance
accuracy shown in the central cell (<33 %)
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cerebellum were predominantly weighted in favour of the ke-
tamine group whilst nodes in the frontal, occipital, parietal,
temporal and medial temporal lobe regions were weighted for
the placebo state. Post hoc univariate tests confirm the direc-
tionality of these effects, revealing decreasing cortical central-
ity and an increase in centrality of the cerebellum and basal
ganglia in the ketamine state relative to the control.
Previous studies have revealed findings consistent with ob-
servations from this study. An overall increase in “global con-
nectivity” as a result of ketamine infusion was observed in
healthy volunteers (Driesen et al. 2013). Regions exhibiting
the greatest increase in this global connectivity for ketamine
included the thalamus, parietal regions and cerebellum.Whilst
our analysis is multivariate, it is noteworthy that the same
regions are present in the pattern of features describing keta-
mine and have increased degree centrality in relation to pla-
cebo. Our analysis extends these previous works, revealing
the pattern on changes across the whole brain between groups.
Ketamine has also been reported to strongly affect the con-
nectivity of cerebellar, visual, auditory, somatosensory and
subcortical regions in relation to pre-defined networks of in-
terest (Niesters et al. 2012). The cerebellum was shown to
have increased connectivity in relation to visual networks as
well as the intra-network connectivity of the visual cortex
when under the influence of ketamine. Furthermore, the thal-
amus, PFC, temporal cortex and cingulum were shown to
have decreasing connectivity in relation to the auditory and
somatosensory network.
The multivariate results presented here provide an alterna-
tive perspective on the effect of acute ketamine on whole-
brain connectivity. The task-free connectivity organisation of
the brain is radically altered by acute ketamine with both in-
creases and decreases in the centrality pattern of the brain.
This is supported by previous studies demonstrating ketamine
administration can cause long-range decoupling of neural
population activity in mouse neocortical slices and has been
shown to cause both increases and decreases in connectivity,
e.g. (Dawson et al. 2013). We can summarise the observed
effects of acute ketamine in humans as a shifting of the pattern
of connectivity from a cortically centred state to a sub-corti-
cally centred state. It is possible that cortical regions have a
global reduction in connectivity with the rest of the brain,
resulting in a reduction in the connectivity of cortical hubs;
alternatively, it is possible that dominant regional couplings
are reduced, resulting in a more equally distributed connectiv-
ity. Both mechanisms would result in the DC pattern observed
under ketamine. The presented methodology is not designed
to identify changes in individual connections; instead, we re-
veal consistent patterns of DC change across the whole brain
which reveals a subcortical contribution for the ketamine con-
nectivity pattern.
The observed pattern of disconnectivity of the cortical hubs
is consistent with many of the experiential effects observed
with ketamine; interruption of connectivity between cortical
hubs would be predicted to result in a reduction contextual
processing, impaired memory, spatial representation and sen-
sorimotor processing. Whilst not a phenocopy of the disorder,
ketamine has been used as pharmacological model for schizo-
phrenia which has been shown to exhibit similar alterations in
connectivity, notably a reduction in high DC cortical hubs
(Rubinov et al. 2009) and wide spread disconnections across
the brain (Liang et al. 2006; Lynall et al. 2010).
The main effects of ketamine at sub-anaesthetic doses
are typically attributed to its blockade of the NMDA re-
ceptor (Driesen et al. 2013). It has high affinity for
NMDA and D2 receptor sites as well as a slightly lower
affinity for the 5-HT2A receptor, muscarinic and opioid
receptors although these are thought to have notable ef-
fects at higher doses only (Hirota et al. 1999; Narita et al.
2001). A possible mechanism by which ketamine effects
connectivity changes is through interruption of NMDAR-
mediated transmission, namely the known cortical micro-
circuit effects where parvalbumin-positive GABAergic in-
terneurons disinhibited by ketamine (Homayoun and
Moghaddam 2007). Microdialysis confirms the NMDA
antagonists PCP and MK-801 increase extracellular GABA
levels. These interneurons inhibit pyramidal cells and syn-
chronise their oscillations (Homayoun and Moghaddam
2007). The disinhibition of these GABAergic interneurons
may result in impaired pyramidal synchrony and hence in
decreased connectivity of cortical nodes, leading to the
observed pattern of centrality. It is suggested that the lat-
eral posterior pulvinar in the thalamus may strongly con-
tribute to pyramidal synchrony (Shumikhina and
Molotchnikoff 1999) which may explain its inclusion in
the pattern for ketamine exhibiting increased centrality.
Alternatively, if ketamine increases cortical connectivity
globally whilst reducing strong regional connections, this
may also result in increased centrality of the basal ganglia
and cerebellum whilst reducing cortical centrality.
The radical alteration of the pattern of centrality during a
task-free ketamine infusion has not been demonstrated previ-
ously and suggests a complex network reorganisation under-
pinning the effect of ketamine, even at the low dose adminis-
tered in this study. This reorganisation is a plausible candidate
for the variety of effects produced by ketamine, such as per-
ceptual distortion (via parietal and visual regions as well as
cerebellar and basal ganglia timing nodes), cognitive
disorganisation (via fronto-patietal nodes) and anhedonia
(via striatal and ventromedial nodes). The important contribu-
tion of the current study is to inform on the reorganisation of
brain networks by ketamine and to what degree these can be
pharmacologically modulated by different pharmacological
mechanisms. In order to facilitate multiple administrations of
ketamine, doses were kept relatively low; as such, we did not
observe any strong and consistent subjective effects.
4214 Psychopharmacology (2015) 232:4205–4218
Furthermore, the sparseness and inconsistencies of participant
subjective responses, which were collected, prohibited inves-
tigation of correlation between functional connectivity effects
and subjective ratings. Replication using higher doses produc-
ing stronger subjective changes in all participants would be
important and also allow testing of the relationship between
the multivariate changes in network patterns with the profiles
of changes in subjective reporting of drug effects.
Lamotrigine treatment
Lamotrigine causes a reduction in glutamate release primarily
through Na+ channel modulation; we hypothesised that this
would partially counter the downstream glutamatergic effects
of ketamine, thus attenuating any ketamine-induced changes
in functional connectivity. Indeed, it has been demonstrated
that lamotrigine pre-treatment attenuates the ketamine BOLD
effect (Deakin et al. 2008; Doyle et al. 2013a; b). Furthermore,
it has been suggested that ketamine’s effect on functional
connectivity may reflect glutamatergic modulation (Duncan
et al. 2011). In contrast to our previous findings on the
ketamine-induced BOLD signal, we found no significant
effects of lamotrigine on the pattern of DC in the brain.
The administered dose of lamotrigine (300 mg) is clinical-
ly effective and the data analysed is the same as that used
in our previous study (Doyle et al. 2013a; b) where clear
effects on the local BOLD signal were demonstrated. In-
stead, our combined results show that lamotrigine induces
an amplitude change in signal rather than affecting the
coupling between regions; although we cannot preclude
more subtle, localised changes in connectivity which our
method which interrogates whole brain DC patterns would
be insensitive. This lack of DC modulation by lamotrigine
is further supported by the ordinal regression of saline,
lamotrigine+ketamine and ketamine conditions, where we
did not observe an ordinal progression between classes.
This is consistent with our conclusion that lamotrigine
does not attenuate the ketamine-induced pattern of DC.
The strong confusion between the lamotrigine+ketamine
and ketamine conditions as observed using binary classifi-
cation whereby the discrimination between the
lamotrigine+ketamine conditions was not significant (Ta-
ble 3) and for ordinal regression (Table 5) whereby ~41 %
of the lamotrigine+ketamine cases were classified as
ketamine.
These results have important mechanistic implications for
the ketamine-induced connectivity response and support the
conclusion that lamotrigine pre-treatment has a similar effect
to placebo on ketamine-induced DC. Furthermore, since
lamotrigine, which block glutamate release, does not signifi-
cantly modulate the ketamine-induced effects then this sug-
gests that the observed pattern of hub connectivity induced by
ketamine reflects NMDAR antagonism per se rather than
downstream glutamatergic effects at non-NMDA sites. In-
stead, this would favour the NMDA blockade of ketamine as
responsible for the observed connectivity changes. This pro-
posal could be confirmed in preclinical experiments using
specific NMDA subunit antagonists and non-NMDA antago-
nists for the AMPA and kainate receptors.
Risperidone treatment
Risperidone (2 mg) is expected to achieve high occupancy of
5-HT2A and D2 receptors (Nyberg et al. 1999) and reduces
glutamate levels downstream through 5-HT2A antagonism.
Furthermore, risperidone has also been reported to potentiate
NMDAR function directly (Konradsson et al. 2006). Given
this profile, we expected that risperidone pre-treatment would
attenuate the pattern of DC induced by ketamine.
Indeed, our observations indicate that, in contrast to
lamotrigine, risperidone modulates the effect of keta-
mine resulting in a pattern of DC distinct to both keta-
mine and saline. The classification maps for ketamine
compared to saline and ketamine compared to ris+keta-
mine also reveal a strong overlap in the spatial distri-
bution, but not amplitude, of weights with the exception
of occipital regions. This is consistent with risperidone
pre-treatment reversing the ketamine-induced node
strength changes. Comparing the pre- and post-infusion
conditions for ketamine pre-treated with risperidone re-
veal risperidone effects some more subtle changes that
did not achieve statistical significance. Direct compari-
son of the ketamine and ris+ketamine states reveal
strong effects of the risperidone pre-treatment on the
ketamine-induced pattern of DC which appear to oppose
the ketamine effect. Furthermore, the ORGP results sug-
gest risperidone does not attenuate the ketamine DC
response in an ordinal manner; instead, the combined
results support the conclusion that risperidone may have
an opposing effect on the ketamine response.
We theorise that it is the twofold mechanism of risperidone
acting upon ketamine that is responsible for the observed DC
effects. It is likely that the potentiation of the NMDAR is the
primary mechanism due to the dissimilarity in resultant effects
between risperidone and lamotrigine pre-treatment. Our re-
sults are suggestive that risperidone may interact with, and
in opposition to, the ketamine resulting in a pattern of DC
dissimilar to that of ketamine; the dissimilarity from the saline
state and ordinal regression results preclude a linear attenua-
tion effect of risperidone on ketamine. These observations
may be predominantly due to serotonergic effects; however,
further work is required using a compound with selective 5-
HT2A binding.
In addition to the NMDA receptor, ketamine also has af-
finity for other receptors including dopamine, D2 and opioid
receptors, particularly at high doses, effects can also be
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elicited through downstream serotonergic and muscarinic re-
ceptors (Hirota et al. 1999; Narita et al. 2001). Whilst we
cannot preclude effects at other receptors contributing to our
findings, we would favour a major contribution from gluta-
matergic effects. The opposing effects of ketamine and risper-
idone in the striatum may conceivably be related to their op-
posing effects at the D2 receptor, where risperidone acts as an
antagonist and ketamine an agonist. The use of selective com-
pounds would be required to understand the contribution of
individual receptor types to the observed pattern of effects.
Stability of pattern recognition method in the absence
of pharmacological intervention
Importantly, our methodology did not detect changes in con-
nectivity pattern when no pharmacological stimulus was ap-
plied. Comparisons between pre-infusion scans from the two
oral placebo sessions (PLA+SAL vs. PLA+KET), as well as
between the pre- and post-infusion scans from the saline infu-
sion session (PLA+SAL), both revealed no significant differ-
ences with classification accuracies approximating chance
level. This test-retest stability provides confidence in our in-
terpretation of the effects of ketamine and its modulation by
risperidone and lamotrigine as reflecting the pharmacological
action of these interventions.
Limitations
The results presented here provide an informative insight into
the mechanisms of effect of ketamine on the human brain;
however, the limitations of this analysis must also be consid-
ered. The use of graph theory combined with machine learn-
ing is a novel approach; it provides a principled means of
investigation pharmacological compounds on the human
brain. The use of centrality, whilst providing an intuitive mea-
sure of regional connectedness and providing an elegant solu-
tion to the interpreting spatial patterns of discrimination, pro-
hibits investigation into specific regional coupling. As such,
this methodology is insensitive to subtle changes in regional
coupling which may be induced by the administered com-
pounds. Univariate methods (Niesters et al. 2012) are avail-
able for testing hypotheses about specific connections, but
these might also be more sensitive to non-pharmacological
effects. Our choice of examining the patterns of change across
the brain was motivated by the widespread expression of
NMDA receptors.
The use of a single connectivity metric and temporal scale
is a further limitation. The use of correlation allows for the
identification of positive and negative synchronous relation-
ships between regions, however, is naive to phase-delayed and
non-linear relationships between regions which are likely to
exist in a complex biological system such as the brain. By
comparing the results of analysis using both correlation and
a phase insensitive measures such as coherence, it may be
possible to infer the effects of ketamine on BOLD signal syn-
chronisation between regions. It is likely that analysis per-
formed using different windowing scales would provide fur-
ther insight into the effects of ketamine on the dynamics of
connectivity in the human brain.
The use of degree centrality provides an initial investiga-
tion into the connectivity effects of ketamine in the brain.
However, in order to generate a complete view of the connec-
tivity effects of ketamine, a range comprehensive range of
measures should be compared. Several graph theory metrics
exist informing differential aspects of function connectivity;
however, many of these measures are highly correlated and
present challenges in biological interpretation. Further inves-
tigation is required in order to identify an optimal set of ortho-
normal connectivity measure suitable for use in connectivity
analysis which provides a broad overview of connectivity
effects.
Conclusions
We have demonstrated a robust pattern of acute connectivity
changes resulting from administration of a sub-anaesthetic
dose of ketamine, comprising a reduction in connectivity of
cortical nodes and an increase in DC of nodes in the basal
ganglia and cerebellum. Importantly, our methodology detect-
ed no changes in the connectivity pattern for paired compari-
sons involving no pharmacological stimulus.
Furthermore, pre-treatment with risperidone, but not
lamotrigine, resulted in a strong modulation of the keta-
mine-induced hub changes. This likely reflects the distinct
mechanisms of the two compounds and suggests that the
observed changes in connectivity are more likely a result
of NMDA blockade and possible serotonergic modulation
rather than purely modulation of glutamate release. The
differential modulatory effects of these two compounds
are in contrast to the finding that both compounds simi-
larly attenuate the ketamine-evoked BOLD signal ampli-
tude changes (De Simoni et al. 2013; Doyle et al. 2013a).
This connectivity analysis provides distinct information re-
garding the effects of neurologically active compounds
and inform on the neural circuit correlates of specific
pharmacological mechanisms.
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